57489-70-0

Basic information

• Product Name: Pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione
• Synonyms: pyrazolo[1,5-a]pyrimidine-5,7-diol;7-hydroxy-1h-pyrazolo[1,5-a]pyrimidin-5-one;Pyrazolo[1,5-a]pyrimidine-5,7-ol;7-Hydroxypyrazolo[1,5-a]pyrimidin-5(4H)-one;5-Hydroxy-4H-pyrazolo[1,5-a]pyrimidin-7-one
• CAS NO: 57489-70-0
• Molecular Formula: C₆H₅N₃O₂
• Molecular Weight: 151.124
• EINECS: 604-604-1
• Mol File: 57489-70-0.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 290.61 °C at 760 mmHg
• Flash Point: 129.556 °C
• Appearance: /
• Density: 1.741 g/cm³
• Refractive Index: 1.793
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione(57489-70-0)
• EPA Substance Registry System: Pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione(57489-70-0)

Safety Data

• Hazardous Substances Data: 57489-70-0(Hazardous Substances Data)

Usage

General Description

Pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione is a chemical compound with the molecular formula C7H5N3O2. It is a heterocyclic compound that contains a pyrazolo-pyrimidine core structure. Pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione has been studied for its potential pharmaceutical applications, particularly in the development of drugs for the treatment of various diseases. It has shown activity as an anti-inflammatory and analgesic agent, as well as potential use in the treatment of cancer due to its ability to inhibit certain enzymes and pathways involved in tumor growth. Research on the synthesis and biological activities of pyrazolo[1,5-a]pyrimidine-5,7(4H,6H)-dione continues, with potential for future pharmaceutical development.

InChI:InChI=1/C6H5N3O2/c10-5-3-6(11)9-4(8-5)1-2-7-9/h1-2H,3H2,(H,8,10)

Upstream product

• 1225387-53-0 3⁽⁵⁾-aminopyrazole 
• 105-53-3 diethyl malonate 
• 1820-80-0 3-aminopyrazole 
• 140-88-5 ethyl acrylate 

Downstream Products

• 57489-77-7 5,7-dichloropyrazolo[1,5-a]pyrimidine 
• 1421271-38-6 C₂₉H₂₅N₉O 
• 1421271-46-6 5-((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)-3-(6-phenylpyridin-3-yl)-8-pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine 
• 58347-52-7 3,5,7-trichloropyrazolo[1,5-a]pyrimidine 
• 1393882-08-0 7-N-(3-chloro-4-fluorophenyl)-5-N-(piperidin-4-ylmethyl)pyrazolo[1,5-a]pyrimidine-5,7-diamine 
• 1393882-07-9 5-N-(4-aminophenyl)-7-N-(3-chloro-4-fluorophenyl)pyrazolo[1,5-a]pyrimidine-5,7-diamine 
• 1393882-05-7 7-N-(3-chloro-4-fluorophenyl)-5-N-cyclohexylpyrazolo[1,5-a]pyrimidine-5,7-diamine 
• 1393882-18-2 5-chloro-N-(3-chloro-4-fluorophenyl)-N-methylpyrazolo[1,5-a]pyrimidin-7-amine 
• 1393882-54-6 tert-butyl N-(2-chlorophenyl)-N-{5-chloropyrazolo[1,5-a]pyrimidin-7-yl}carbamate 
• 1393882-37-5 tert-butyl N-(3-chloro-4-fluorophenyl)-N-{5-chloropyrazolo[1,5-a]pyrimidin-7-yl} carbamate 
• 1393882-35-3 5-chloro-N-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-amine 

Relevant articles and documents

Synthesis of two novel pyrazolo[1,5-a]pyrimidine compounds with antibacterial activity and biophysical insights into their interactions with plasma protein

Two novel water-soluble pyrazolo[1,5-a]pyrimidine derivatives, 5-chloro-7-(4-methyl-piperazin ?1-yl)-pyrazolo[1,5-a]pyrimidine (CMPS) and N′-(5-chloro-pyrazolo[1,5-a]pyrimidin-7-yl)-N,N-dimethyl -propane-1,3-diamine (NCPS), were synthesized and characterized with antibacterial activity. Then, the interactions of these compounds with bovine serum albumin (BSA) were studied by fluorescence, time-resolved fluorescence, circular dichroism (CD) spectroscopy and molecular docking. The results indicate that both CMPS and NCPS could effectively quench the intrinsic fluorescence of BSA via a static quenching process. The energy transfer from BSA to CMPS and NCPS may occur with high probability. Both CMPS and NCPS bind in the site I of BSA. The hydrophobic force and hydrogen bonds play major roles in the complex formation. Binding constants for both systems show that the affinity of CMPS binding to BSA is stronger than that of NCPS. The results of three-dimensional fluorescence and CD spectra reveal that the binding of CMPS and NCPS to BSA can induce conformational changes of BSA, and the influence of CMPS is slightly stronger than that of NCPS.

TYK2 PSEUDOKINASE LIGANDS

Described herein are TYK2 pseudokinase ligands and methods of utilizing TYK2 pseudokinase ligands in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.